Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
October 30, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
October 02, 2023 07:00 ET
|
Cabaletta Bio
– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis features...
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
September 19, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
August 30, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
August 22, 2023 08:00 ET
|
Cabaletta Bio
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – – Partnership...
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET
|
Cabaletta Bio
– Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN – – Strengthened balance sheet by closing $100M public offering extending cash...
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
July 24, 2023 08:00 ET
|
Cabaletta Bio
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE...
Cabaletta Bio to Present at the Jefferies Healthcare Conference
May 31, 2023 08:00 ET
|
Cabaletta Bio
PHILADELPHIA, May 31, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
May 22, 2023 16:30 ET
|
Cabaletta Bio
PHILADELPHIA, May 22, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first...
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
May 17, 2023 22:16 ET
|
Cabaletta Bio
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first...